scispace - formally typeset
R

Rufus S. Day

Researcher at Cross Cancer Institute

Publications -  62
Citations -  5949

Rufus S. Day is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: DNA repair & DNA. The author has an hindex of 27, co-authored 62 publications receiving 5904 citations. Previous affiliations of Rufus S. Day include Kyoto University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line

TL;DR: The radiosensitive rodent mutant cell line xrs-5 is defective in DNA double-strand break repair and lacks the Ku component of the DNA-activated protein kinase, DNA-PK, which suggests that DNA- PK kinase activity is involved in DNAdouble-stranded break repair.
Journal ArticleDOI

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains

TL;DR: It is reported that Mer− strains are deficient in removing O6-methylguanine (O6-MeG) from their DNA after [Me-14C]MNNG treatment and originate from tumours arising in patients having Mer+ normal fibroblasts.
Journal ArticleDOI

Human tumor cell strains defective in the repair of alkylation damage.

TL;DR: Two human astrocytoma cell strains as defective in the repair of N-methyl-N' -nitro-N-nitrosoguanidine (MNNG) damaged adenovirus 5 are shown to be very sensitive to MNNG-produced killing as measured by colony forming ability, but are normally sensitive to ultraviolet light.
Journal ArticleDOI

Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.

TL;DR: Two aneuploid cell lines which differ in their inherent sensitivity to ionizing radiation and chemotherapeutic agents were established concurrently from a single tumor specimen obtained from a patient with glioblastoma may prove to provide a useful model system for evaluating the cellular and molecular processes which confer resistance or sensitivity in cancer treatment.